“…Compared to amsacrine, AHMA has longer half‐life in human plasma accompanied by longer duration of its drug action (Rastogi et al., 2002). AHMA was also shown to display better antitumor activity in vivo probably due to the substituent (NH 2 and CH 2 OH, Figure 1) arrangement in the meta‐positions of the aniline ring, which prevents undesired oxidation processes (Afzal, Sarfraz, Wu, Wang, & Sun, 2016; Chang et al., 2003).…”